The results from this study provide significant clinical evidence of the performance of Viraleze™ in humans that will support regulatory processes for the transition to the new European Medical Device Regulations (MDR), which will come into full effect in 2029. The positive data will also support ongoing marketing and commercial activities for the product.
just because something isn’t statistically significant doesn’t mean the results aren’t meaningful.
- Forums
- ASX - By Stock
- Sarge'lost shirt
The results from this study provide significant clinical...
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
|
|||||
Last
9.7¢ |
Change
0.002(2.11%) |
Mkt cap ! $40.06M |
Open | High | Low | Value | Volume |
9.6¢ | 9.7¢ | 9.6¢ | $1.323K | 13.80K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 259 | 9.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.7¢ | 39000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 259 | 0.096 |
2 | 69731 | 0.095 |
2 | 305855 | 0.094 |
2 | 320000 | 0.093 |
1 | 100000 | 0.092 |
Price($) | Vol. | No. |
---|---|---|
0.097 | 39000 | 1 |
0.098 | 275000 | 2 |
0.100 | 106000 | 3 |
0.105 | 148467 | 3 |
0.110 | 183058 | 5 |
Last trade - 10.51am 10/09/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |